Access

Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Content from this campaign

Illumina Invests in £30M Venture Fund To Advance Breakthroughs in Human Health
SAN DIEGO, June 28, 2022, /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health. Illumina...
Jun 29, 2022 10:00 AM ET
Australia's PrOSPeCT Project Is Sequencing Thousands of Cancer Patients
This March, Australia launched the Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT), which will sequence the genomes of more than 20,000 cancer patients, many with rare and challenging tumors. The $185 million AUD (about $127 million USD) project will unite Australian federal and state governments, hospitals, research organizations, and biopharma companies to direct...
Jun 24, 2022 10:00 AM ET
Illumina Launches Research Test Codeveloped With Merck To Unlock Deeper Insights Into the Tumor Genome
SAN DIEGO, June 22, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada). The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to...
Jun 22, 2022 1:00 PM ET
AI Drives Data Insights for Doctors and Their Patients
Dr. Lina Basel-Salmon has been treating rare disease patients at Schneider Children’s Medical Center of Israel and Beilinson Hospital at the Rabin Medical Center for 22 years. In the city of Petah Tikva where she practices, Dr. Basel-Salmon was...
Jun 14, 2022 10:30 AM ET
“All Patients Should Have Their Tumor Sequenced At Least Once”
This year’s American Society of Clinical Oncology (ASCO) 2022 Annual Meeting took place in person at the Hyatt Regency in Chicago and online, June 3-7. Thousands of oncology professionals, patient advocates, and industry representatives convened for the world’s largest clinical oncology meeting to discuss the latest scientific and...
Jun 13, 2022 1:10 PM ET

Pages